The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical features and outcomes of secondary somatic malignancy (SSM) associated with primary mediastinal nonseminomatous germ cell tumors (PM-NSGCT).
 
Lucas W. Dean
No Relationships to Disclose
 
Nathan Colin Wong
No Relationships to Disclose
 
Shawn Dason
No Relationships to Disclose
 
Sumit Isharwal
No Relationships to Disclose
 
Mark Donoghue
No Relationships to Disclose
 
Liwei Jia
No Relationships to Disclose
 
William D. Tap
Leadership - Atropos; Certis Oncology Solutions
Stock and Other Ownership Interests - Atropos; Certis Oncology Solutions
Consulting or Advisory Role - Agios; Blueprint Medicines; Daiichi Sankyo; Eisai; EMD Serono; GlaxoSmithKline; Immune Design; Janssen; Lilly; Loxo; Novartis; Plexxikon
Research Funding - Blueprint Medicines; Daiichi Sankyo; Immune Design; Lilly; Novartis; Plexxikon; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Companion Diagnostic for CDK4 inhibitors - 14/854,329; Methods of Treating Metastatic Sarcoma Using Talimogene Laherparepvec (T-Vec) and Pembrolizumab Combination Therapy- 62/671,625
 
Gabriella Joseph
No Relationships to Disclose
 
Samuel Aaron Funt
Stock and Other Ownership Interests - Allogene Therapeutics; Allogene Therapeutics; Hubble (I); Kite, a Gilead company; Second Science; Urogen pharma (I)
Research Funding - AstraZeneca; Genentech/Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Deaglan Joseph McHugh
No Relationships to Disclose
 
Hikmat Al-Ahmadie
Consulting or Advisory Role - Bristol-Myers Squibb; EMD Serono
 
Victor E. Reuter
No Relationships to Disclose
 
Joel Sheinfeld
No Relationships to Disclose
 
Dean F. Bajorin
Honoraria - Merck Sharp & Dohme
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; EMD Serono; Fidia Farmaceutici S. p. A.; Genentech; Lilly; Lilly; Merck; Novartis; Pfizer; Roche; Roche/Genentech; Urogen pharma
Research Funding - Amgen (Inst); Astellas Pharma; AstraZeneca; Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); dendreon (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Seattle Genetics/Astellas
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck; Roche/Genentech; Urogen pharma
 
Robert J. Motzer
Consulting or Advisory Role - Eisai; Exelixis; Genentech/Roche; Incyte; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); Novartis (Inst); Pfizer (Inst)
 
George J. Bosl
No Relationships to Disclose
 
Manjit S. Bains
No Relationships to Disclose
 
David Randolph Jones
No Relationships to Disclose
 
David B. Solit
Consulting or Advisory Role - Illumina; Intezyne Technologies; Loxo; Pfizer; Vividion Therapeutics
Travel, Accommodations, Expenses - Merck KGaA
 
Darren R. Feldman
Research Funding - Novartis; Seagen
Other Relationship - UpToDate